The company’s net income for FY23 was $3.76bn. Credit: JHVEPhoto / Shutterstock.com.

Medtronic has reported a revenue of $31.23bn in fiscal year 2023 (FY23), down by 1.4% from $31.69bn in FY22.

The cardiovascular divisions posted a 1.3% rise in revenue to $11.57bn in FY23, compared to $11.42bn in the prior year.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The medical surgical divisions witnessed a 7.7% drop in revenue to $8.43bn during the year from $9.14bn in FY22.

Medtronic reported a 2% year-over-year revenue growth for its neuroscience business in FY23 to $8.96bn, while the revenue of its diabetes divisions fell by 3.3% from $2.33bn to $2.26bn.

During the fiscal year, the company’s net income declined by 25.2% year-over-year to $3.76bn.

The diluted earnings per share was $2.82, down by 24% from $3.73 in FY22.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The cash flow from operations for FY23 amounted to $6.039bn, marking an 18% decrease year-over-year, while the free cash flow during the same period fell by 23% year-over-year to $4.58bn.

Medtronic chairman and CEO Geoff Martha said: “We had a strong finish to our fiscal year, with our fourth quarter top and bottom-line results coming in ahead of expectations.

“Our accelerating revenue growth was broad-based, driven by procedure volume recovery, supply improvements and innovative product introductions.”

In the fourth quarter (Q4) of FY23, the company recorded a revenue of $8.54bn, reflecting a 5.6% increase compared to the same period a year ago.

Its Q4 organic revenue was driven by solid performances in its medical surgical, neuroscience and cardiovascular portfolios, as well as in diabetes markets outside the US.

During the quarter, the net income fell by 21% to $1.18bn, against $1.49bn in Q4 of FY22.

In its financial outlook for FY24, Medtronic projects its organic revenue growth to be between 4% and 4.5%.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact